Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
11.52
-0.06 (-0.52%)
At close: Apr 6, 2026, 4:00 PM EDT
11.38
-0.14 (-1.22%)
Pre-market: Apr 7, 2026, 7:26 AM EDT
Schrödinger Revenue
In the year 2025, Schrödinger had annual revenue of $255.87M with 23.29% growth. Schrödinger had revenue of $87.24M in the quarter ending December 31, 2025, a decrease of -1.23%.
Revenue (ttm)
$255.87M
Revenue Growth
+23.29%
P/S Ratio
3.32
Revenue / Employee
$301,022
Employees
850
Market Cap
850.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 255.87M | 48.33M | 23.29% |
| Dec 31, 2024 | 207.54M | -9.13M | -4.21% |
| Dec 31, 2023 | 216.67M | 35.71M | 19.73% |
| Dec 31, 2022 | 180.96M | 43.02M | 31.19% |
| Dec 31, 2021 | 137.93M | 29.84M | 27.60% |
| Dec 31, 2020 | 108.10M | 22.55M | 26.36% |
| Dec 31, 2019 | 85.54M | 18.90M | 28.37% |
| Dec 31, 2018 | 66.64M | 10.95M | 19.65% |
| Dec 31, 2017 | 55.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.53B |
| Omnicell | 1.18B |
| GoodRx Holdings | 796.85M |
| Phreesia | 480.59M |
| Certara | 418.84M |
| HealthStream | 304.06M |
| Omada Health | 260.21M |
| Weave Communications | 239.02M |
SDGR News
- 19 days ago - Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results - Business Wire
- 5 weeks ago - Schrödinger to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1 - Benzinga
- 7 weeks ago - Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25 - Business Wire
- 3 months ago - Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities - Business Wire
- 3 months ago - Schrodinger to offer Eli Lilly's AI drug discovery platform on its software - Reuters
- 3 months ago - Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign - Business Wire